ArticleJournal of natural medicines2026
Ginsenoside Rk3 modulates glutamine metabolism and inhibits Th17 cell differentiation via gut microbiota regulation to ameliorate psoriasis.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dysbiosis of the gut microbiota has been demonstrated to trigger immune responses that may heighten psoriasis susceptibility. However, conventional therapies for psoriasis are often limited by significant side effects. Ginsenoside Rk3 (Rk3), a bioactive triterpenoid glycoside compound derived from natural ginseng, has shown promise as a potent immunomodulator and gut regulator. Therefore, this study aims to investigate the potential protective effect of Rk3 against psoriasis, with a focus on the gut microbiota modulation and immune response regulation. Network pharmacology was first employed to predict potential targets for the action of Rk3 on psoriasis and an imiquimod (IMQ)-induced psoriasis mice model was used to investigate the palliative effect of Rk3 on psoriasis. Our results reveal that Rk3 restores gut microbiota homeostasis, especially modulating the abundance of Akkermansia muciniphila and Parabacteroides distasonis, and effectively alleviates IMQ-induced psoriasis through gut microbiota-dependent mechanisms. Furthermore, Rk3 exerts a regulatory effect on aberrant amino acid metabolism, suppressing glutamine catabolism while enhancing short-chain fatty acids (SCFAs) biosynthesis. Rk3-mediated regulation of glutamine metabolism exerts an inhibition effect on the conversion of glutamine to glutamate, suppresses Th17 cell differentiation and alleviates psoriasis via the IL-6/JAK1-STAT3 signaling axis. Overall, our research elucidates Rk3's mechanism of action in ameliorating psoriasis and highlights its potential as a gut microbiota modulator for psoriasis treatment.
Indexed as
Identifiers
42766261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.